靶向免疫检查点的肿瘤免疫治疗现状与趋势

任军; 黄红艳

doi:10.3969/j.issn.1000-8179.20140359

靶向免疫检查点的肿瘤免疫治疗现状与趋势

doi: 10.3969/j.issn.1000-8179.20140359

任军^,,
黄红艳

首都医科大学附属北京世纪坛医院肿瘤中心，首都医科大学肿瘤医学院，肿瘤治疗性疫苗北京市重点实验室（北京市 100038）

基金项目:

北京市科委科技创新基地培育与发展工程项目 Z131102002813059

详细信息

作者简介:
任军医学博士，主任医师，二级教授，肿瘤学、免疫学博士导师。曾任第四军医大学西京医院肿瘤中心主任、北京大学肿瘤医院大内科主任。现任首都医科大学肿瘤学系常务副主任、首都医科大学附属北京世纪坛医院院长助理、肿瘤中心主任。担任肿瘤治疗性疫苗北京市重点实验室主任。曾赴美国哈佛大学任高级访问学者，2008年10月至今为美国杜克大学肿瘤中心正式教职员。致力于肿瘤转化研究20年，建立了“化疗联合免疫治疗”的临床治疗模式。发表学术论文216篇，其中SCI 50篇

通讯作者:
任军 renjun9688@yahoo.com

计量
- 文章访问数: 59
- HTML全文浏览量: 28
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2014-02-13
- 修回日期: 2014-04-03
- 刊出日期: 2014-04-15

Current situation and trends in blockade of targeted immune checkpoints in cancer immunotherapy

REN Jun^,,
HUANG Hongyan

Comprehensive Cancer Center, Beijing Shijitan Hospital of Capital Medical University (CMU), CMU College of Oncology; Bei jing Key Laboratory of Cancer Therapeutic Vaccine, Beijing 100038, China

More Information

Corresponding author: Jun REN; E-mail: renjun9688@yahoo.com

摘要

摘要: 针对免疫检查点的阻断是众多激活抗肿瘤免疫的有效策略之一。免疫检查点是指免疫系统中存在的一些抑制性信号通路，通过调节外周组织中免疫反应的持续性和强度避免组织损伤，并参与维持对于自身抗原的耐受。利用免疫检查点的抑制性信号通路抑制T细胞活性是肿瘤逃避免疫杀伤的重要机制。细胞毒性T淋巴细胞相关抗原-4（cytotoxic T lymphocyte-associated antigen-4，CTLA-4）抗体Ipilimumab是首个被美国FDA批准靶向免疫检查点的治疗药物，对其他的免疫检查点如程序性死亡蛋白-1（programmed death protein-1，PD-1）及其配体的抑制能够有效治疗多种肿瘤，而且能诱发持续的肿瘤缓解。靶向免疫检查点在抗肿瘤免疫治疗中有着广阔的应用前景，由于经典的化疗药物具有免疫调节作用，使得免疫治疗与化疗的联合成为新的趋势。
- 肿瘤 /
- 免疫治疗 /
- 化疗 /
- 免疫检查点 /
- 免疫调节
Abstract: The blockade of targeted immune checkpoint is one of the most promising approaches to activate therapeutic antitumor immunity. The immune checkpoint refers to a plethora of inhibitory pathways in the immune system. These pathways are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues to minimize collateral tissue damage. Tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance. Cytotoxic T-lymphocyte-associated antigen 4 antibodies were the first of this class of immunotherapeutics to acquire approval from the US Food and Drug Administration. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1, indicate broad and diverse opportunities to enhance anti-tumor immunity with the potential to produce durable clinical responses. Classic chemotherapy exerts significant immunomodulatory effects on tumor cells via multiple mechanisms. Therefore, the combination of immunotherapy, including immune checkpoint blockade with chemotherapy, is a new promising trend in anti-tumor immunotherapy.
- cancer /
- immunotherapy /
- chemotherapy /
- immunocheckpoint /
- immunomodulation

HTML全文

参考文献(30)

[1]	Motz GT, Coukos G. Deciphering and reversing tumor immune suppression[J]. Immunity, 2013, 39(1):61-73. doi: 10.1016/j.immuni.2013.07.005
[2]	Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation[J]. Nat Rev Drug Discov, 2013, 12(2):130-146. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=591051e96ba20099266943ce52ff2592
[3]	Pardoll DM. The blockade of immune checkpoints in cancer immu notherapy[J]. Nat Rev Cancer, 2012, 12(4):252-264. doi: 10.1038/nrc3239
[4]	Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of con ventional and targeted anticancer therapies: reinstating immunosur veillance[J]. Immunity, 2013, 39(1):74-88. doi: 10.1016/j.immuni.2013.06.014
[5]	Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity[J]. Cancer Immunol Immunother, 2013, 62(2):203-216. doi: 10.1007/s00262-012-1388-0
[6]	Boland JM, Kwon ED, Harrington SM, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung[J]. Clin Lung Cancer, 2013, 14(2):157-163. http://www.ncbi.nlm.nih.gov/pubmed/22868219
[7]	Wang L, Qian J, Lu Y, et al. Immune evasion of mantle cell lym phoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells[J]. Haematologica, 2013, 98(9):1458-1466. doi: 10.3324/haematol.2012.071340
[8]	Flies DB, Wang S, Xu H, et al. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-ver sus-host disease in mouse models[J]. J Immunol, 2011, 187(4): 1537-1541. doi: 10.4049/jimmunol.1100660
[9]	Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8):711-723. http://neuro-oncology.oxfordjournals.org/external-ref?access_num=20525992&link_type=MED
[10]	Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival[J]. Ann Oncol, 2013, 24(6):1697-1703. doi: 10.1093/annonc/mdt027
[11]	Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl J Med, 2013, 369(2):134-144. doi: 10.1056/NEJMoa1305133
[12]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and im mune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 66(26):2443-2454. https://pubmed.ncbi.nlm.nih.gov/22658127/
[13]	Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of an ti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26):2455-2465. doi: 10.1056/NEJMoa1200694
[14]	Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 block ade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial[J]. Lancet Oncol, 2014, 15(1):69-77. doi: 10.1016/S1470-2045(13)70551-5
[15]	Jayaraman P, Sada-Ovalle I, Beladi S, et al. Tim3 binding to galec tin-9 stimulates antimicrobial immunity[J]. J Exp Med, 2010, 207 (11):2343-2354. doi: 10.1084/jem.20100687
[16]	Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tu mor immunity[J]. J Exp Med, 2010, 207(10):2187-2194. doi: 10.1084/jem.20100643
[17]	Jackaman C, Majewski D, Fox SA, et al. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vi vo[J]. Cancer Immunol Immunother, 2012, 61(12):2343-2356. doi: 10.1007/s00262-012-1307-4
[18]	Wan S, Pestka S, Jubin RG, et al. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells[J]. PLoS One, 2012, 7(3):e32542. doi: 10.1371/journal.pone.0032542
[19]	Galluzzi L, Senovilla L, Zitvogel L, et al. The secret ally: immunos timulation by anticancer drugs[J]. Nat Rev Drug Discov, 2012, 11(3): 215-233. doi: 10.1038/nrd3626
[20]	Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies[J]. Mol Cancer Ther, 2012, 11(1):3-13. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=1234271717fb8bb81ce8dc7019479939
[21]	Ramakrishnan R, Huang C, Cho HI, et al. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immu notherapy[J]. Cancer Res, 2012, 72(21):5483-5493. doi: 10.1158/0008-5472.CAN-12-2236
[22]	Banissi C, Ghiringhelli F, Chen L, et al. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model[J]. Cancer Immunol Immunother, 2009, 58(10):1627-1634. doi: 10.1007/s00262-009-0671-1
[23]	Chen CA, Ho CM, Chang MC, et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulato ry T lymphocytes and inhibiting tumor angiogenesis[J]. Mol Ther, 2010, 18(6):1233-1243. doi: 10.1038/mt.2010.34
[24]	Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy[J]? Br J Cancer, 2009, 100(11): 1697-1703. http://www.tandfonline.com/servlet/linkout?suffix=CIT0104&dbid=8&doi=10.1586%2Fera.10.66&key=19384299
[25]	Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophos phamide regimen selectively depletes CD4⁺ CD25⁺ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J]. Cancer Immunol Immunother, 2007, 56(5):641-648. doi: 10.1007/s00262-006-0225-8
[26]	Shurin GV, Tourkova IL, Kaneno R, et al. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by den dritic cells via an IL-12-dependent mechanism[J]. J Immunol, 2009, 183(1):137-144. doi: 10.4049/jimmunol.0900734
[27]	Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction[J]. J Clin Oncol, 2011, 29(6):610-618. doi: 10.1200/JCO.2010.30.5425
[28]	DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexi ty predicts breast cancer survival and functionally regulates re sponse to chemotherapy[J]. Cancer Discov, 2011, 1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028
[29]	Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and re sponse to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis[J]. J Clin Oncol, 2012, 30(16):1996-2004. doi: 10.1200/JCO.2011.39.5624
[30]	Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemother apy in breast cancer[J]. J Clin Oncol, 2010, 28(1):105-113. doi: 10.1200/JCO.2009.23.7370